Søren Lemonius, founder and managing partner at Sunstone Life Science Ventures, shares the story of how he and his team initiated the Danish VC firm’s investment strategy that has lead to a number of very successful exits – and to some very costly losses. He also reveals why early-stage deals often yield the best returns (”because you’re selling a multiple of a dream”), explains why venture capital thrives in times of crisis and shares the one major reason for why some investments never materialise. We ponder the concept of longevity and find out what Søren considers to be the next hot areas to invest in, why IPOs are not a prefered exit option for Sunstone’s investments and why venture capital firms usually thrive in times of crisis.
Podden och tillhörande omslagsbild på den här sidan tillhör BioStock. Innehållet i podden är skapat av BioStock och inte av, eller tillsammans med, Poddtoppen.
